PILOT-STUDY FOR PROFILING PSA GLYCOSYLATION AS PUTATIVE PROSTATE CANCER BIOMARKER BY HIGH RESOLUTION NATIVE MASS SPECTROMETRY

Completed

• Conditions: Prostate Cancer; 10038597

• Registration Number: NL-OMON42143
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

Inclusion criteria for patients:
-Male gender
-Signed written informed consent
-Biopsy-proven prostate cancer, eligible for surgery
-Age 55 - 70 years
-Willing and able to collect semen;Inclusion criteria for controls:
-Male gender
-Visiting the outpatient clinic because of lower urinary tract symptoms (LUTS)
-Signed written informed consent
-Serum PSA < 3.0 ng/ml
-No suspicion for prostate cancer on digital rectal examination and transrectal ultrasound as judged by the urologist
-Willing and able to collect semen

Exclusion Criteria

-Urinary tract infection

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- PSA-glycosylation patterns (finger-prints) for prostate cancer versus normal<br /><br>controls<br /><br>- Correlation between PSA-glycosylation patterns and Gleason grade/tumour stage<br /><br>(clinical and pathological)</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Correlation between PSA-glycosylation patterns and PSA-level in serum</p><br>